PlainPill

BPC-157 vs MK-2866 for recovery

Short answer: For recovery, users rate them about the same: 96% report improvement with BPC-157 (337 reports) and 97% with MK-2866 (60 reports).

BPC-157 has 0 meta-analyses and 0 randomized trials on PubMed; MK-2866 has 0 and 0.

Based on 1,150 reports about BPC-157 and 603 about MK-2866. Not medical advice.

BPC-157
Peptide
MK-2866
SARM
User score4733
Verdict
Mixed
Mixed
Positive
of reports that state an outcome
53%39%
Reports1,150603
ResearchDResearch: NoneDResearch: None
Meta-analyses / RCTs0 / 00 / 0
Mainly used for
Weight loss
% reporting improvement
70% (10)89% (79)
Appetite
% reporting improvement
70% (10)62% (8)
Focus
% reporting improvement
62% (26)71% (7)
Energy
% reporting improvement
59% (29)54% (37)
Sleep
% reporting improvement
71% (52)20% (20)
Anxiety
% reporting improvement
43% (56)33% (9)
Mood
% reporting improvement
58% (104)62% (48)
Memory
% reporting improvement
33% (3)—
Performance
% reporting improvement
93% (44)87% (189)
Recovery
% reporting improvement
96% (337)97% (60)
Pain & inflammation
% reporting improvement
84% (366)70% (27)
Digestion
% reporting improvement
84% (85)—
Libido
% reporting improvement
54% (13)31% (45)
Hormones
% reporting improvement
20% (5)4% (82)
Heart & lipids
% reporting improvement
46% (13)0% (8)
Skin & hair
% reporting improvement
89% (27)33% (6)
Immunity
% reporting improvement
62% (8)—
Common side effectsanhedonia, fatigue, anxiety, depressionsuppression, fatigue, insomnia, headache
Typical dose reportedNot listedNot listed
BPC-157
What a user said
“a few people said they stacked TB-500 and BPC-157 without issues”
Full BPC-157 profile →
MK-2866
What a user said
“Ostarine suppresses your natural testosterone just like an aas would”
Full MK-2866 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate